Clinical efficacy of tigecycline combined with isepamicin in treatment of multidrug-resistant Acinetobacter baumannii pneumonia
- VernacularTitle:替加环素联合异帕米星治疗多重耐药鲍曼不动杆菌肺炎的疗效观察
- Author:
Wei WANG
;
Chunzhen HUA
- Publication Type:Journal Article
- Keywords:
tigecycline;
isepamicin;
combination therapy;
multidrug-resistant Acinetobacter baumannii pneumonia
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;37(4):148-150
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of tigecycline combinated with isepamicin for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii.Methods A retrospective analysis was performed in adult patients with multidrug-resistant Acinetobacter baumannii pneumonia in two general hospitals from January 2012 to January 2014.Total eighty-four patients with MDR-Acinetobacter baumannii pneumonia were randomly divided into two groups(n=42).One group was treated with tigecycline combinated with isepamicin(termed combination therapy group),and another group was administrated with cefoperazone sulbactam (termed control group ).The clinical cure rates,microbiological eradication rates and adverse events were collected and compared. Results There was no difference in APACHEⅡ score between two groups.The clinical cure rates in combination therapy group was significantly higher than that in control group(88% vs 61%,P<0.05),and with a higher rate of microbiological eradication(59.5% vs 35.7%,P <0.05 ).However,the occurence rate of adverse events was similar in the two groups (7.1% vs 1 1.9%). Conclusion With a higher rate of clinical efficacy and a lower rate of adverse events,the combination therapy with tigecycline and isepamicin would be a promising alternative for treatment with MDR-Acinetobacter baumannii pneumonia.
